Marietta Wu
Algemeen Directeur bij Burrill & Co. Venture Capital
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Guo-Liang Yu | M | 62 |
The BayHelix Group
Innoforce Pharmaceuticals Co. Ltd.
Innoforce Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Innoforce Pharmaceuticals Co. Ltd. is a bioinnovation-enabling corporation located in the Hangzhou Bay Biotech Valley within the Hangzhou Airport Economic Demonstration Area. The founders and core management team have extensive international experience and expertise in technology innovation, product development, and business operations. The Chinese company's first phase of the campus covers 21 acres, including biologic process development laboratories, scale-up and R & D labs, and manufacturing facilities for protein, cell, and gene therapies. The company was founded in 2018 by Guo-Liang Yu, Yuling Li, and Zhenhua Wu. Dewan Zeng has been the CEO of the company since 2023. | - |
Yuling Li | M | - |
Innoforce Pharmaceuticals Co. Ltd.
Innoforce Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Innoforce Pharmaceuticals Co. Ltd. is a bioinnovation-enabling corporation located in the Hangzhou Bay Biotech Valley within the Hangzhou Airport Economic Demonstration Area. The founders and core management team have extensive international experience and expertise in technology innovation, product development, and business operations. The Chinese company's first phase of the campus covers 21 acres, including biologic process development laboratories, scale-up and R & D labs, and manufacturing facilities for protein, cell, and gene therapies. The company was founded in 2018 by Guo-Liang Yu, Yuling Li, and Zhenhua Wu. Dewan Zeng has been the CEO of the company since 2023. | - |
Jin Zhong Zhang | M | - |
Eluminex Biosciences (Suzhou) Ltd.
Eluminex Biosciences (Suzhou) Ltd. BiotechnologyHealth Technology Eluminex Biosciences (Suzhou) Ltd. is a privately held biotechnology company located in Suzhou, China. Eluminex Biosciences is committed to developing innovative pharmaceuticals, drug delivery systems, and regenerative tissue for significant unmet vision-threatening or lifestyle limiting ophthalmic diseases in various markets. The Chinese company focuses on ophthalmology and recombinant human collagen technology, with a goal to become a leading healthcare company in developing irreversible loss of optical quality of the cornea due to disease or damage, diabetic macular edema, and wet age-related macular degeneration. The company was founded in 2020 by Jin Zhong Zhang, who has been the CEO since then. | 4 jaar |
Ying Du | M | 59 | 10 jaar | |
Ya Fei Zhang | M | - |
MEDx Translational Medicine Co., Ltd.
MEDx Translational Medicine Co., Ltd. Medical DistributorsDistribution Services MEDx Translational Medicine Co., Ltd. is a leading Chinese innovative company in companion diagnostics and precision medicine in China. The company is based in Suzhou, China. MEDx collaborates with hundreds of world-renowned pharmaceutical companies and has been rewarded with many certifications, including China CNAS, ISO17025, and US CAP ISO 13485, among others. The company was founded in 2013 as Qiagen Translational Medicine Co., Ltd. With comprehensive technology platforms, high-quality systems, and strong IVD R&D experience, MEDx offers integrated solutions from biomarker discovery to patient stratification for drug clinical trials, IVD/CDX R&D, and commercialization. The company was founded in 2013 by Ya Fei Zhang, who has been the CEO since then. | 11 jaar |
Kai Xian Chen | M | 78 | 6 jaar | |
John Diekman | M | 81 | 7 jaar | |
Theodora Caroline Harold | F | 50 |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | 8 jaar |
Shawn Xiang | M | - |
Shanghai Rarestone Health Tech Group Co. Ltd.
Shanghai Rarestone Health Tech Group Co. Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Rarestone Health Tech Group Co. Ltd. is a Chinese company that focuses on rare disease therapy and self-management information through internet information. The company is based in Huangpu, China. The company also operates and promote medical devices and communication platforms. The CEO of the company is Shawn Xiang. | - |
Zhenhua Wu | M | - |
Innoforce Pharmaceuticals Co. Ltd.
Innoforce Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Innoforce Pharmaceuticals Co. Ltd. is a bioinnovation-enabling corporation located in the Hangzhou Bay Biotech Valley within the Hangzhou Airport Economic Demonstration Area. The founders and core management team have extensive international experience and expertise in technology innovation, product development, and business operations. The Chinese company's first phase of the campus covers 21 acres, including biologic process development laboratories, scale-up and R & D labs, and manufacturing facilities for protein, cell, and gene therapies. The company was founded in 2018 by Guo-Liang Yu, Yuling Li, and Zhenhua Wu. Dewan Zeng has been the CEO of the company since 2023. | - |
Graziano Seghezzi | M | 55 |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | - |
Victor Shi | M | - |
The BayHelix Group
| - |
Wing Yu Leung | F | 53 | 10 jaar | |
Peter Wirth | M | 73 | 7 jaar | |
Brian McGuinness | M | - |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | - |
Hongbo Lu, PhD | - | - |
Shanghai Rarestone Health Tech Group Co. Ltd.
Shanghai Rarestone Health Tech Group Co. Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Rarestone Health Tech Group Co. Ltd. is a Chinese company that focuses on rare disease therapy and self-management information through internet information. The company is based in Huangpu, China. The company also operates and promote medical devices and communication platforms. The CEO of the company is Shawn Xiang. | - |
Yun Zhang | F | 40 |
The BayHelix Group
| - |
Mahendra Shah | M | 79 |
Shanghai Rarestone Health Tech Group Co. Ltd.
Shanghai Rarestone Health Tech Group Co. Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Rarestone Health Tech Group Co. Ltd. is a Chinese company that focuses on rare disease therapy and self-management information through internet information. The company is based in Huangpu, China. The company also operates and promote medical devices and communication platforms. The CEO of the company is Shawn Xiang. | - |
Kwing-Ming Tsoi | M | - |
Innoforce Pharmaceuticals Co. Ltd.
Innoforce Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Innoforce Pharmaceuticals Co. Ltd. is a bioinnovation-enabling corporation located in the Hangzhou Bay Biotech Valley within the Hangzhou Airport Economic Demonstration Area. The founders and core management team have extensive international experience and expertise in technology innovation, product development, and business operations. The Chinese company's first phase of the campus covers 21 acres, including biologic process development laboratories, scale-up and R & D labs, and manufacturing facilities for protein, cell, and gene therapies. The company was founded in 2018 by Guo-Liang Yu, Yuling Li, and Zhenhua Wu. Dewan Zeng has been the CEO of the company since 2023. | - |
Zeng Liu | F | - |
Innoforce Pharmaceuticals Co. Ltd.
Innoforce Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Innoforce Pharmaceuticals Co. Ltd. is a bioinnovation-enabling corporation located in the Hangzhou Bay Biotech Valley within the Hangzhou Airport Economic Demonstration Area. The founders and core management team have extensive international experience and expertise in technology innovation, product development, and business operations. The Chinese company's first phase of the campus covers 21 acres, including biologic process development laboratories, scale-up and R & D labs, and manufacturing facilities for protein, cell, and gene therapies. The company was founded in 2018 by Guo-Liang Yu, Yuling Li, and Zhenhua Wu. Dewan Zeng has been the CEO of the company since 2023. | - |
Teri Loxam | F | 52 |
Kira Pharmaceuticals (Hong Kong) Ltd.
Kira Pharmaceuticals (Hong Kong) Ltd. Pharmaceuticals: MajorHealth Technology Kira Pharmaceuticals (Hong Kong) Ltd. manufactures pharmaceuticals. The private company is based in Hong Kong, Hong Kong. | 3 jaar |
MinChuan Wang | M | - |
Shanghai Rarestone Health Tech Group Co. Ltd.
Shanghai Rarestone Health Tech Group Co. Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Rarestone Health Tech Group Co. Ltd. is a Chinese company that focuses on rare disease therapy and self-management information through internet information. The company is based in Huangpu, China. The company also operates and promote medical devices and communication platforms. The CEO of the company is Shawn Xiang. | - |
Stephen Lin | M | - |
Eluminex Biosciences (Suzhou) Ltd.
Eluminex Biosciences (Suzhou) Ltd. BiotechnologyHealth Technology Eluminex Biosciences (Suzhou) Ltd. is a privately held biotechnology company located in Suzhou, China. Eluminex Biosciences is committed to developing innovative pharmaceuticals, drug delivery systems, and regenerative tissue for significant unmet vision-threatening or lifestyle limiting ophthalmic diseases in various markets. The Chinese company focuses on ophthalmology and recombinant human collagen technology, with a goal to become a leading healthcare company in developing irreversible loss of optical quality of the cornea due to disease or damage, diabetic macular edema, and wet age-related macular degeneration. The company was founded in 2020 by Jin Zhong Zhang, who has been the CEO since then. | - |
Chun Yan Zhang | F | - |
Eluminex Biosciences (Suzhou) Ltd.
Eluminex Biosciences (Suzhou) Ltd. BiotechnologyHealth Technology Eluminex Biosciences (Suzhou) Ltd. is a privately held biotechnology company located in Suzhou, China. Eluminex Biosciences is committed to developing innovative pharmaceuticals, drug delivery systems, and regenerative tissue for significant unmet vision-threatening or lifestyle limiting ophthalmic diseases in various markets. The Chinese company focuses on ophthalmology and recombinant human collagen technology, with a goal to become a leading healthcare company in developing irreversible loss of optical quality of the cornea due to disease or damage, diabetic macular edema, and wet age-related macular degeneration. The company was founded in 2020 by Jin Zhong Zhang, who has been the CEO since then. | - |
Yuan Hua Ding | M | 61 |
The BayHelix Group
| - |
Yi Ning Zhao | M | 53 |
The BayHelix Group
| 13 jaar |
Rebecca Lin | F | - |
Shanghai Rarestone Health Tech Group Co. Ltd.
Shanghai Rarestone Health Tech Group Co. Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Rarestone Health Tech Group Co. Ltd. is a Chinese company that focuses on rare disease therapy and self-management information through internet information. The company is based in Huangpu, China. The company also operates and promote medical devices and communication platforms. The CEO of the company is Shawn Xiang. | - |
Igor Matushansky | M | 51 |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | 6 jaar |
Harald Reinhart | M | 72 | 7 jaar | |
Kevin Johnson | M | - |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | - |
Ting Xie | M | - |
Eluminex Biosciences (Suzhou) Ltd.
Eluminex Biosciences (Suzhou) Ltd. BiotechnologyHealth Technology Eluminex Biosciences (Suzhou) Ltd. is a privately held biotechnology company located in Suzhou, China. Eluminex Biosciences is committed to developing innovative pharmaceuticals, drug delivery systems, and regenerative tissue for significant unmet vision-threatening or lifestyle limiting ophthalmic diseases in various markets. The Chinese company focuses on ophthalmology and recombinant human collagen technology, with a goal to become a leading healthcare company in developing irreversible loss of optical quality of the cornea due to disease or damage, diabetic macular edema, and wet age-related macular degeneration. The company was founded in 2020 by Jin Zhong Zhang, who has been the CEO since then. | - |
James Xue | M | 55 |
The BayHelix Group
| - |
Jun Wu | M | 58 |
Jing Medicine Technology Shanghai Ltd.
Jing Medicine Technology Shanghai Ltd. BiotechnologyHealth Technology Jing Medicine Technology Shanghai Ltd. develops therapeutic monoclonal antibody and small molecule drugs. The private company is based in Shanghai, China. | - |
Chong Xu | M | 43 |
Shanghai Rarestone Health Tech Group Co. Ltd.
Shanghai Rarestone Health Tech Group Co. Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Rarestone Health Tech Group Co. Ltd. is a Chinese company that focuses on rare disease therapy and self-management information through internet information. The company is based in Huangpu, China. The company also operates and promote medical devices and communication platforms. The CEO of the company is Shawn Xiang. | - |
Ming Guo | M | 67 |
The BayHelix Group
| - |
Daniel Bach | M | - |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | 6 jaar |
Eva-Lotta Allan | F | 65 |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | 6 jaar |
Gilles Nobécourt | M | 67 |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | - |
Yi You Chen | M | - |
The BayHelix Group
| - |
Jinzi Wu | M | 61 |
The BayHelix Group
| - |
Dewan Zeng | M | - |
Innoforce Pharmaceuticals Co. Ltd.
Innoforce Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Innoforce Pharmaceuticals Co. Ltd. is a bioinnovation-enabling corporation located in the Hangzhou Bay Biotech Valley within the Hangzhou Airport Economic Demonstration Area. The founders and core management team have extensive international experience and expertise in technology innovation, product development, and business operations. The Chinese company's first phase of the campus covers 21 acres, including biologic process development laboratories, scale-up and R & D labs, and manufacturing facilities for protein, cell, and gene therapies. The company was founded in 2018 by Guo-Liang Yu, Yuling Li, and Zhenhua Wu. Dewan Zeng has been the CEO of the company since 2023. | 1 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Tao Fu | M | 52 | 5 jaar | |
Jian Ming Yu | M | 52 | - | |
Yong Jiang Hei | M | 61 | 3 jaar | |
Qi Liu | F | - | - | |
Ki Chul Cho | M | 46 | 5 jaar | |
Minghui Chen | M | - | - | |
Yi Liang | M | 53 | 6 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
China | 18 | 37.50% |
Kaaimaneilanden | 13 | 27.08% |
Verenigde Staten | 9 | 18.75% |
Verenigd Koninkrijk | 8 | 16.67% |
Hongkong | 1 | 2.08% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Marietta Wu
- Persoonlijk netwerk